Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD A JACKSON

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1578644290
CMS profile
344186
Location
RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,346.49

165 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,626.50 163
Consulting Fee $640.00 1
Education $79.99 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD A JACKSON

NPI 1578644290 · CMS profile ID 344186

Allopathic & Osteopathic Physicians / Internal Medicine

RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578644290?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD A JACKSON, NPI 1578644290, CMS profile ID 344186. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578644290?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). RICHARD A JACKSON, NPI 1578644290, CMS profile ID 344186. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578644290?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
RICHARD A JACKSON, NPI 1578644290, CMS profile ID 344186, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 165 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1578644290?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

165 matching records · $3,346.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 165 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 165.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer HealthCare Pharmaceuticals Inc. $17.5408/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789132215 CMS
AbbVie Inc. $18.5108/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932819 CMS
GlaxoSmithKline, LLC. $0.6908/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803049495 CMS
GlaxoSmithKline, LLC. $11.6208/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803081679 CMS
AbbVie Inc. $4.3108/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932815 CMS
Biohaven Pharmaceuticals, Inc. $15.1408/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852525741 CMS
AbbVie Inc. $12.3908/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932811 CMS
AbbVie Inc. $16.1108/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932807 CMS
Amgen Inc. $15.5007/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825718875 CMS
AbbVie Inc. $15.0107/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932803 CMS
Astellas Pharma US Inc $15.0507/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821377985 CMS
Alexion Pharmaceuticals, Inc. $19.7107/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783134931 CMS
Mylan Specialty L.P. $14.3007/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965423585 CMS
AbbVie Inc. $14.0807/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932799 CMS
AstraZeneca Pharmaceuticals LP $640.0007/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829353631 CMS
Biohaven Pharmaceuticals, Inc. $23.6107/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852525739 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.8707/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850410597 CMS
AbbVie Inc. $13.9307/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932795 CMS
AbbVie Inc. $3.7707/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932791 CMS
Novartis Pharmaceuticals Corporation $12.0707/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812730169 CMS
AbbVie Inc. $14.7707/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932787 CMS
Amarin Pharma Inc. $20.6407/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815121893 CMS
GlaxoSmithKline, LLC. $10.5506/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802988837 CMS
AbbVie Inc. $19.6506/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932783 CMS
Amgen Inc. $13.4506/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825718887 CMS
Mylan Specialty L.P. $12.1506/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965420235 CMS
Merck Sharp & Dohme Corporation $13.3006/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848412855 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.6006/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850393683 CMS
AbbVie Inc. $14.7306/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932779 CMS
Janssen Pharmaceuticals, Inc $11.4406/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788407099 CMS
AbbVie Inc. $3.5606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932775 CMS
AbbVie Inc. $13.8806/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932771 CMS
AbbVie Inc. $3.8206/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932767 CMS
Vanda Pharmaceuticals Inc. $22.3706/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838902201 CMS
Sunovion Pharmaceuticals Inc. $18.0106/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821720827 CMS
AbbVie Inc. $12.0705/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932763 CMS
AbbVie Inc. $12.3905/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932759 CMS
AstraZeneca Pharmaceuticals LP $11.2805/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829566113 CMS
PFIZER INC. $14.0405/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833454877 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.7905/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850035977 CMS
AbbVie Inc. $19.1005/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932755 CMS
Astellas Pharma US Inc $11.6705/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821377981 CMS
AstraZeneca Pharmaceuticals LP $14.0405/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830108635 CMS
AbbVie Inc. $14.1505/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932751 CMS
AbbVie Inc. $23.1705/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794932747 CMS
AstraZeneca Pharmaceuticals LP $13.8105/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829424429 CMS
GlaxoSmithKline, LLC. $5.9605/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802891591 CMS
Esperion Therapeutics, Inc. $11.8705/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838318695 CMS
GlaxoSmithKline, LLC. $16.7204/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802603177 CMS
Insulet Corporation $14.1104/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839825421 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,952.35 112
PY2020 $2,018.82 118
PY2021 $3,346.49 165
PY2022 $2,449.01 150
PY2023 $2,145.69 105
PY2024 $2,045.01 74
PY2025 $1,851.06 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $536,919.14 38
PY2024 Principal investigator $430,772.86 52
PY2023 Recipient $2,912.76 2
PY2023 Principal investigator $735,676.95 111
PY2022 Recipient $8,126.00 2
PY2022 Principal investigator $279,780.82 157
PY2021 Recipient $1,684.04 1
PY2021 Principal investigator $75,744.80 5
PY2020 Principal investigator $141,499.58 210
PY2019 Principal investigator $289,719.52 138

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $9,108.34 12/31/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC.
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1232920560
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 12/11/2025 Non-covered Recipient Entity
Dominion Medical Associates Inc-Downtown
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220996970
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Dominion Medical Associates Inc-Downtown
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220715913
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 11/25/2025 Non-covered Recipient Entity
Dominion Medical Associates Inc-Downtown
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220806709
Principal investigator 1 Novartis Pharmaceuticals Corporation $36.81 11/15/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190302899
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9,800.00 11/05/2025 Non-covered Recipient Entity
Dominion Medical Associates - ClinEdge - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508485
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,598.00 11/05/2025 Non-covered Recipient Entity
Dominion Medical Associates - ClinEdge - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508489
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,639.24 11/05/2025 Non-covered Recipient Entity
EAST FLORIDA EYE INSTITUTE
A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) No dispute reported 06/30/2026 1190309444
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Dominion Medical Associates Inc-Downtown
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220715905
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 11/01/2025 Non-covered Recipient Entity
Dominion Medical Associates Inc-Downtown
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220715907
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 11/01/2025 Non-covered Recipient Entity
Dominion Medical Associates Inc-Downtown
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220715909
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 11/01/2025 Non-covered Recipient Entity
Dominion Medical Associates Inc-Downtown
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220715911
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,697.00 10/15/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185541052
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,040.76 10/08/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190302895
Principal investigator 1 Eli Lilly and Company $17,714.00 10/07/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF MUVALAPLIN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE HAD A PRIOR ATHEROSCLEROTIC CARDIOVASCULAR EVENT OR ARE AT RISK FOR A FIRST ATHEROSCLEROTIC CARDIOVASCULAR EVENT – MOVE-LP(A) No dispute reported 06/30/2026 1187879961
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,000.00 10/01/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC
A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure No dispute reported 06/30/2026 1190304009
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,800.00 10/01/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES INC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309446
Principal investigator 1 Novartis Pharmaceuticals Corporation $912.59 09/03/2025 Non-covered Recipient Entity
EAST FLORIDA EYE INSTITUTE
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190313579
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,065.00 06/12/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190304007
Principal investigator 1 Eli Lilly and Company $225.00 04/23/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187878857
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,405.61 03/31/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190302893
Principal investigator 1 Novo Nordisk AS $17,521.85 03/31/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC
EX9924-4473 No dispute reported 06/30/2026 1213819918
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,876.89 03/11/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190304001
Principal investigator 1 Novartis Pharmaceuticals Corporation $44,930.04 03/05/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190302897
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $40,475.24 03/03/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES INC.
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214124540
Principal investigator 1 Novo Nordisk AS $1,700.00 02/21/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC
EX9924-4473 No dispute reported 06/30/2026 1213727367
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,472.54 02/06/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190302903
Principal investigator 1 Novartis Pharmaceuticals Corporation $43,958.04 02/04/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190304005
Principal investigator 1 Novo Nordisk AS $525.00 01/31/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC
EX9924-4473 No dispute reported 06/30/2026 1213773687
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,376.00 01/30/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190303999
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,013.85 01/29/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185541050
Principal investigator 1 Eli Lilly and Company $33,900.00 01/28/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187883652
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,290.00 01/28/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190304003
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,110.47 01/15/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190302901
Principal investigator 1 Eli Lilly and Company $1,476.00 01/09/2025 Non-covered Recipient Entity
LIGHTSHIP INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885984
Principal investigator 1 Eli Lilly and Company $7,338.00 01/07/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187881142
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,000.00 01/07/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES, INC
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension No dispute reported 06/30/2026 1190304011
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $125,614.70 01/01/2025 Non-covered Recipient Entity
DOMINION MEDICAL ASSOCIATES INC.
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214125404